Type 2 diabetes
Conditions
Interventions
Lixisenatide group: In type 2 diabetic patients treated with multiple insulin injection therapy, discontinue rapid-acting insulin and add on lixisenatide at 20ug. Continue basal insulin.
Multiple i
Sponsors
Hokkaido University Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients whose HbA1c were >=6.0%, <9.0%, type 2 diabetic patients 2) Patients treated with multiple insulin injection therapy for more than 3 months 3) Patients whose total dose of daily insulin were <=30 units.
Exclusion criteria
Exclusion criteria: 1) Patients who have history of diabetic ketoacidosis, or diabetic coma in the past 6 months 2) Patients who are pregnant or in lactation period 3) Patients with serious infectious disease, before operation, serious trauma 4) Patients who receive steroid therapy 5) Patients with severe liver dysfunction 6) Patients with type 1 diabetes 7) Patients with disorder of insulin secretion whose fasting serum C-peptide <0.5ng/ml 8) Patients with hypersensitivity to these medicines 9) Patients who have history of pancreas disease 10) Patients who have history of cancer 11) Patients receiving with GLP-1 receptor agonist or he DPP-4 inhibitor in the past 3 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Diabetes Treatment Satisfaction Questionnaire(DTSQ) at 0 and 12 weeks after switching from multiple insulin injection therapy to combination therapy with lixisenatide and basal insulin | — |
Secondary
| Measure | Time frame |
|---|---|
| The daily profile of blood glucose, changes of HbA1c and body weight at 0 and 12 weeks after switching from multiple insulin injection therapy to combination therapy with lixisenatide and basal insulin Incidence of hypoglycemia | — |
Countries
Japan
Contacts
Public ContactAkinobu Nakamura
Hokkaido University Hospital Department of Internal Medicine II
Outcome results
None listed